Eli Lilly Shares Down 7.5% as Market Reacts to Slashed Q4 Forecast
Shares of Eli Lilly ( NYSE:LLY) are down 7.6% today, reflecting market disappointment in the company's adjusted guidance for the fourth quarter of 2024. The pharmaceutical giant expects only $13.5 billion in revenue for Q4 2024, compared to the consensus estimate of $13.97 billion.
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, ...
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Guggenheim lowered the firm’s price target on Eli Lilly (LLY) to $973 from $995 and keeps a Buy rating on the shares. The firm is updating its ...
The London Metal Exchange is in its final stages to approve Hong Kong as the main warehousing network for its metals.
Citing lower-than-expected sales for its weight-loss medicine Zepbound and diabetes treatment Mounjaro, Eli Lilly ( NYSE:LLY) ...
Berenberg analyst Kerry Holford lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,050 and keeps a Buy rating on the shares.
Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback